Cargando…

Advanced MRI Assessment during Dendritic Cell Immunotherapy Added to Standard Treatment against Glioblastoma

Evaluating changes induced by immunotherapies (IT) on conventional magnetic resonance imaging (MRI) is difficult because those treatments may produce inflammatory responses. To explore the potential contribution of advanced MRI to distinguish pseudoprogression (PsP) and true tumor progression (TTP),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cuccarini, Valeria, Aquino, Domenico, Gioppo, Andrea, Anghileri, Elena, Pellegatta, Serena, Schettino, Carla, Mazzi, Federica, Finocchiaro, Gaetano, Bruzzone, Maria Grazia, Eoli, Marica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912338/ https://www.ncbi.nlm.nih.gov/pubmed/31744235 http://dx.doi.org/10.3390/jcm8112007

Ejemplares similares

MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives
por: Aquino, Domenico, et al.
Publicado: (2017)

ABCC3 Expressed by CD56(dim) CD16(+) NK Cells Predicts Response in Glioblastoma Patients Treated with Combined Chemotherapy and Dendritic Cell Immunotherapy
por: Pellegatta, Serena, et al.
Publicado: (2019)

The natural killer cell response and tumor debulking are associated with prolonged survival in recurrent glioblastoma patients receiving dendritic cells loaded with autologous tumor lysates
por: Pellegatta, Serena, et al.
Publicado: (2013)

Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
por: Eoli, Marica, et al.
Publicado: (2019)

Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8(+) T cell activation in the presence of adjuvant temozolomide
por: Pellegatta, Serena, et al.
Publicado: (2018)

P12. Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
por: Pellegatta, S, et al.
Publicado: (2014)

Parametric Response Maps of Perfusion MRI May Identify Recurrent Glioblastomas Responsive to Bevacizumab and Irinotecan
por: Aquino, Domenico, et al.
Publicado: (2014)

Prognostic Value of CD109+ Circulating Endothelial Cells in Recurrent Glioblastomas Treated with Bevacizumab and Irinotecan
por: Cuppini, Lucia, et al.
Publicado: (2013)

NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma
por: Speranza, Maria Carmela, et al.
Publicado: (2012)

Frequency of NFKBIA deletions is low in glioblastomas and skewed in glioblastoma neurospheres
por: Patanè, Monica, et al.
Publicado: (2013)

Revisiting the Immunological Aspects of Temozolomide Considering the Genetic Landscape and the Immune Microenvironment Composition of Glioblastoma
por: Di Ianni, Natalia, et al.
Publicado: (2021)

Deciphering the Labyrinthine System of the Immune Microenvironment in Recurrent Glioblastoma: Recent Original Advances and Lessons from Clinical Immunotherapeutic Approaches
por: Anghileri, Elena, et al.
Publicado: (2021)

PGE(2) Is Crucial for the Generation of FAST Whole- Tumor-Antigens Loaded Dendritic Cells Suitable for Immunotherapy in Glioblastoma
por: Nava, Sara, et al.
Publicado: (2020)

Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity
por: Cantini, Gabriele, et al.
Publicado: (2012)

CLRM-08 TARGETING IMMUNE-PAYLOAD TO THE GLIOBLASTOMA TUMOR MICROENVIRONMENT USING A MACROPHAGE-BASED TREATMENT RELYING ON AUTOLOGOUS, GENETICALLY MODIFIED, HEMATOPOIETIC STEM CELL-BASED THERAPY: THE TEM-GBM STUDY (NCT03866109)
por: Eoli, Marica, et al.
Publicado: (2022)

An Optimized Method for Manufacturing a Clinical Scale Dendritic Cell-Based Vaccine for the Treatment of Glioblastoma
por: Nava, Sara, et al.
Publicado: (2012)

Case report: Multiple brain intravascular papillary endothelial hyperplasia: incidence, diagnostic challenges, and management approach
por: Anghileri, Elena, et al.
Publicado: (2023)

FOXP3, a novel glioblastoma oncosuppressor, affects proliferation and migration
por: Frattini, Véronique, et al.
Publicado: (2012)

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma
por: Pellegatta, Serena, et al.
Publicado: (2015)

Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO)
por: Padovan, Marta, et al.
Publicado: (2021)

126 novel mutations in Italian patients with neurofibromatosis type 1
por: Bianchessi, Donatella, et al.
Publicado: (2015)

Morphometry and network-based atrophy patterns in SCN1A-related Dravet syndrome
por: Lenge, Matteo, et al.
Publicado: (2023)

Glioblastomas
por: Finocchiaro, Gaetano, et al.
Publicado: (2021)

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study
por: Brandes, Alba A., et al.
Publicado: (2017)

Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme
por: Yang, Liu, et al.
Publicado: (2015)

A Radial Glia Gene Marker, Fatty Acid Binding Protein 7 (FABP7), Is Involved in Proliferation and Invasion of Glioblastoma Cells
por: De Rosa, Antonella, et al.
Publicado: (2012)

MET inhibition overcomes radiation resistance of glioblastoma stem‐like cells
por: De Bacco, Francesca, et al.
Publicado: (2016)

A Subpopulation of Circulating Endothelial Cells Express CD109 and is Enriched in the Blood of Cancer Patients
por: Mancuso, Patrizia, et al.
Publicado: (2014)

Towards an Established Intraoperative Oncological Favorable Tool: Results of Fluorescein-Guided Resection from a Monocentric, Prospective Series of 93 Primary Glioblastoma Patients
por: Falco, Jacopo, et al.
Publicado: (2022)

The multidrug-resistance transporter Abcc3 protects NK cells from chemotherapy in a murine model of malignant glioma
por: Pessina, Sara, et al.
Publicado: (2015)

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma
por: Gardam, Bryan, et al.
Publicado: (2023)

Simultaneous Detection of NF1, SPRED1, LZTR1, and NF2 Gene Mutations by Targeted NGS in an Italian Cohort of Suspected NF1 Patients
por: Bianchessi, Donatella, et al.
Publicado: (2020)

Quantitation of normal metabolite concentrations in six brain regions by in-vivo (1)H-MR spectroscopy
por: Minati, Ludovico, et al.
Publicado: (2010)

Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction
por: Di Ianni, Natalia, et al.
Publicado: (2021)

MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy
por: Heugenhauser, Johanna, et al.
Publicado: (2022)

DNA Damage in Mammalian Neural Stem Cells Leads to Astrocytic Differentiation Mediated by BMP2 Signaling through JAK-STAT
por: Schneider, Leonid, et al.
Publicado: (2013)

Dendritic and Langerhans cells respond to Aβ peptides differently: implication for AD immunotherapy
por: Cheng, Jiang, et al.
Publicado: (2015)

Adding value to mechanical ventilation
por: Schettino, Guilherme
Publicado: (2014)

P1359: USING GENE-MODIFIED AUTOLOGOUS STEM CELLS PROGENY TO REEDUCATE THE TUMOR IMMUNE MICROENVIRONMENT OF SOLID TUMORS (TEM-GBM STUDY)
por: Farina, F., et al.
Publicado: (2022)

B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheres
por: Nehama, Dean, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6g5v6gskavsce71rdbv5jnjc5d